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Ni(II)-complexes, derived from glycine Schiff bases with chiral
tridentate ligands, have been used as powerful tools for the
synthesis of structurally diverse tailor-made amino acids. In this
manuscript, asymmetric alkylation reaction between chiral
nucleophilic glycine derived Ni-complex and 3-(chloromethyl)-
1H-pyrrolo[2,3-b]pyridine has been developed under conven-
ient conditions, which affords the corresponding alkylated Ni-
complex in 74% yield and excellent diastereoselectivity (only
one isomer). This reaction features convenient conditions and
completely controlled diastereoselectivity, which provides a
highly valuable approach for asymmetric synthesis of 7-aza-
tryptophan.
Amino acids (AAs) belong to the most ubiquitous class of
naturally occurring compounds,[1] which have been used as an
important type of structural units in the design of modern
drugs due to several advantageous features, such as high
structural diversity, wide scope of functional groups, good
solubility in aqueous media, and few safety concerns.[2]
Currently, a number of small-molecule, peptidomimetics, and
peptide containing residues of tailor-made AAs or their
derivatives serve as key structural features in many blockbuster
drugs.[3] Among these natural and non-natural AAs, 7-aza-
tryptophan occupies an important position, which has been
widely used as biological fluorescent probes,[4] antiplasmodial
compounds,[5] and inhibitors of checkpoint kinase 1.[6,7]
Although there have been several reports on the synthesis of
aza-tryptophanes,[8] the synthesis of 7-aza-tryptophan still
remained less developed, in particular in the asymmetric mode.
One of the first asymmetric methods was based on alkylation
reaction between (1R,4R)-camphor imine and tert-butylglyci-
nate, which proceeded with poor chemical yield (Scheme 1a).[9]
Chemoenzymatic synthesis represents an alternative strategy
for the preparation of optical pure 7-aza-tryptophan using
aspergillus genus acylase,[10] L-amino acid oxidase[11] or trypto-
phan synthase from Salmonella typhimurium[12] as biocatalyst
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(Scheme 1b). Thus, there is a room for the development of
convenient, efficient, and easy scalable methods for preparation
of chiral 7-aza-tryptophan.
Consistent with our long-standing interest in preparation of
tailor-made AAs, in particular phosphorus-[13] and fluorine-
containing derivatives,[14] we were developing general approach
for asymmetric synthesis of AAs via Ni(II) complexes of chiral
Schiff bases.[15] Typically, chiral ligands (S)-5–7 are used for the
preparation of nucleophilic glycine-based Ni-complex for the
introduction of the desired side-chain(s) (Figure 1).[16] Several
types of reactions of these nucleophilic Ni-complexes have
been developed, such as alkyl halide alkylation[17] aldol,[18]
Mannich[19] and Michael[20] addition reactions. Based on the
literature data and our own experience in application of Ni(II)-
complexes of Schiff bases for the synthesis of “Tailor-Made
Amino Acids™”,[21,22] we eversion that reaction between Ni-
complex and suitable alkyl halide would provide a method to
chiral 7-aza-tryptophan. Herein, report an asymmetric method
for the synthesis of chiral 7-aza-tryptophan via an alkylation of
chiral Ni-complex with corresponding alkyl chloride (Sche-
me 1c).
Ligand (S)-6 derived glycine Ni-complex 2 was chosen as
the starting material for this alkylation reaction (Scheme 2),
which usually shows enhanced control in stereoselectivity due
to a parallel displaced type of aromatic interactions between
the selectively chlorinated o-amino-benzophenone and Pro N-
benzyl rings.[23] The desired alkyl chloride 3, Boc-protected 3-
(chloromethyl)-1H-pyrrolo[2,3-b]pyridine, was prepared with
1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde as the starting re-
agent (for details, see SI file).
Having prepared alkyl chloride 3, we then studied its
alkylation reaction with Ni(II)-complex 2 (Scheme 2). To find an
optimal reaction condition to achieve high selectivity and clean
conversion to the desired Ni (II) complex 4a, several screens
were carried out. The optimization study led to the very specific
condition using DMSO as a reaction solvent, which had rarely
been used in the past applications of this methodology.[21]
Using DMSO showed a significant difference in purity of the
product 4a during the reaction, exhibiting the high diastereo-
meric selectivity as well as the lowering impurities formation.
After more refining studies were conducted to find an optimal
stoichiometry of base and alkyl chloride minimizing the key bis-
alkylation byproduct, we found that the reaction with DMSO as
a solvent in the presence of NaOH (1.5 equiv.) and alkyl chloride
(0.8 equiv.) provided the best yield and diastereoselectivity. To
address this question, we added the following sentence: The
beneficial effect of DMSO on the reaction outcome is likely
multifactorial. However, what could be clearly noticed is a
significantly reduced amount of the oxidation products that
usually observed under strongly basic reaction conditions.[24]
During the workup procedure, surprisingly, the Boc group
was partially removed during the reaction even under basic
conditions providing a mixture of compounds (4a and 4b).
Thus, we developed a one-pot procedure for the synthesis of
pure alkylated Ni-complex 4a. The Boc remaining protected
product 4b was completely converted to compound 4a by the
treatment of the crude reaction mixture with MeOH.
Thus, the reaction was conducted in 2.0 g scale of (S)-2,
0.8 equiv. of alkyl chloride 3, 1.5 equiv. of NaOH, in DMSO
(40 mL) under nitrogen atmosphere at room temperature for
1.5 h. The resulted reaction mixture was treated with MeOH
(40 mL) and stirred at 20 °C for 2 h, and then heated to 60 °C for
1 h, which afforded the corresponding product 4a in 74% yield
and completely controlled stereochemical outcome.
The alkylated Ni (II) complex (S,2S)-4a was then disas-
sembled in the presence of 3 N HCl (aqueous) with 1,2-
dimethoxyethane (DME) as a solvent, which afforded the
corresponding free amino acid, (S)-7-aza-tryptophan (1)
hydrochloric acid salt in 95% yield (Scheme 3). DME was chosen
as a solvent, instead of methanol, although methanol has been
generally employed for this step.[22] This is because the use of
methanol as solvent for this disassembly procedure was found
to cause undesired esterification. The reaction proceeded
smoothly, and the isolation of the amino acid was successfully
carried out by filtering off most of the chiral ligand precipitated
after the reaction and partitioning between water and dichloro-
methane to sequester the residual ligand into organics. C18
flash column chromatography was utilized to remove the
residual Ni2+ prior to the following Fmoc protection. It should
be pointed out the C18 flash column method was used during
this trace experiment. This is proved to be the most straightfor-
Figure 1. Chiral tridentate ligands 5–7.
Scheme 2. Alkylation of chiral glycine-Ni(II) complex 2 with compound 3.
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ward for small scale, which worked well to provide the desired
amino acid 1 in good yield and high purity. It should be
emphasized that chiral ligand (S)-6, as well as Ni(II), can be
recycled and reused for continuous production of this and other
types of AAs, as illustrated in the recent publications.[22,25]
The Fmoc protection was carried out employing general
conditions using Fmoc-OSu in the presence of sodium
carbonate (Scheme 4). The reaction proceeded smoothly and
furnished the desired Fmoc-L-7-AzaTrp-OH (8) in 70% yield. It
should be mentioned that the residual Ni2+ seems to
complicate the Fmoc reaction and care must be taken to
remove Ni2+ completely before this step. The crystalline
product 8 was easy to isolate from the reaction. For the
purification, the hydrolyzed impurity derived from unreacted
Fmoc-OSu was effectively sequestered by the trituration with
toluene. The synthesized compound 1 could be easily obtained
with a high chemical purity as measured by 1H-NMR and HPLC.
In summary, the first total synthesis of Fmoc-L-7-AzaTrp-OH
via tridentate chiral auxiliary derived Ni(II)-complexes method-
ology was successfully accomplished, which could be operated
under convenient conditions resulting in an overall 49% yield
(three-step). In particular, excellent diastereoselectivity was
obtained for the alkylation step (only one isomer).
Acknowledgements
We gratefully acknowledge the financial support from the Na-
tional Natural Science Foundation of China (No. 21761132021)
and IKERBASQUE, Basque Foundation for Science.
Conflict of Interest
The authors declare no conflict of interest.
Keywords: Aza-tryptophanes · Asymmetric synthesis · Chiral
tridentate ligands · Ni catalysis · Tailor-Made Amino Acids™ ·
Schiff bases
[1] a) H. B. Vickery, C. L. Schmidt, Chem. Rev. 1931, 9, 169–318; b) M. A. T.
Blaskovich, J. Med. Chem. 2016, 59, 10807–10836; c) Asymmetric
Synthesis and Application of α-Amino Acids, ACS Symposium Series
#1009; V. A. Soloshonok, K. Izawa, Eds., Oxford University Press: 2009;
d) A. Stevenazzi, M. Marchini, G. Sandrone, B. Vergani, M. Lattanzio,
Bioorg. Med. Chem. Lett. 2014, 24, 5349–5356.
[2] a) B. Vig, J. Rautio, Ther. Delivery 2011, 2, 959–962; b) P. Conti, L.
Tamborini, A. Pinto, A. Blondel, P. Minoprio, A. Mozzarelli, C. De Micheli,
Chem. Rev. 2011, 111, 6919–6946.
[3] a) J. Han, A. E. Sorochinsky, T. Ono, V. A. Soloshonok, Curr. Org. Synth.
2011, 8, 281–294; b) H. Mei, J. Han, K. D. Klika, K. Izawa, T. Sato, N. A.
Meanwell, V. A. Soloshonok, Eur. J. Med. Chem. 2020, 186, 111826;
c) V. A. Soloshonok, A. E. Sorochinsky, Synthesis 2010, 2319–2344; d) H.
Mei, J. Han, S. White, D. J. Graham, K. Izawa, T. Sato, S. Fustero, N. A.
Meanwell, V. A. Soloshonok, Chem. Eur. J. 2020, 26, 11349; e) J. Han,
A. M. Remete, L. S. Dobson, L. Kiss, K. Izawa, H. Moriwaki, V. A.
Soloshonok, D. O’Hagan, J. Fluorine Chem. 2020, 239, 109639; f) Z. Yin,
W. Hu, W. Zhang, H. Konno, H. Moriwaki, K. Izawa, J. Han, V. A.
Soloshonok, Amino Acids 2020, 52, 1227; g) J. Liu, J. Han, K. Izawa, T.
Sato, S. White, N. A. Meanwell, V. A. Soloshonok, Eur. J. Med. Chem.
2020, 208, 112736; h) H. Mei, A. M. Remete, Y. Zou, H. Moriwaki, S.
Fustero, L. Kiss, V. A. Soloshonok, J. Han, Chin. Chem. Lett. 2020, 31,
2401; i) H. Mei, J. Han, S. Fustero, M. Medio-Simon, D. M. Sedgwick, C.
Santi, R. Ruzziconi, V. A. Soloshonok, Chem. Eur. J. 2019, 25, 11797; j) J.
Han, H. Konno, T. Sato, V. A. Soloshonok, K. Izawa, Eur. J. Med. Chem.
2021, 220, 113448; k) H. Mei, J. Han, S. White, D. J. Graham, K. Izawa, T.
Sato, S. Fustero, N. A. Meanwell, V. A. Soloshonok, Chem. Eur. J. 2020, 26,
11349–11390; l) W. Qiu, X. Gu, V. A. Soloshonok, M. D. Carducci, V. J.
Hruby, Tetrahedron Lett. 2001, 42, 145–148; m) M. Shevchuk, Q. Wang,
R. Pajkert, J. Xu, H. Mei, G. V. Röschenthaler, J. Han, Adv. Synth. Catal.
2021, doi.org/10.1002/adsc.202001464.
[4] a) V. De Filippis, S. De Boni, E. De Dea, D. Dalzoppo, C. Grandi, A.
Fontana, Protein Sci. 2004, 13, 1489–1502; b) W. C. Chao, T. H. Chiang,
P. D. Chaudhari, L. J. Lin, J. F. Lu, B. C. Hong, J. S. Wang, T. C. Lin, J. Y.
Shen, P. T. Chou, Bioorg. Chem. 2018, 81, 504–511; c) L. D. Newton, S. I.
Pascu, R. M. Tyrrell, I. M. Eggleston, Org. Biomol. Chem. 2019, 17, 467–
471; d) M. G. Hoesl, M. Larregola, H. Cui, N. Budisa, J. Pept. Sci. 2010, 16,
589–595.
[5] T. B. Beghyn, J. Charton, F. Leroux, G. Laconde, A. Bourin, P. Cos, L.
Maes, B. Deprez, J. Med. Chem. 2011, 54, 3222–3240.
[6] L. Gazzard, B. Appleton, K. Chapman, H. Chen, K. Clark, J. Drobnick, S.
Goodacre, J. Halladay, J. Lyssikatos, S. Schmidt, S. Sideris, C. Wiesmann,
K. Williams, P. Wu, I. Yen, S. Malek, Bioorg. Med. Chem. Lett. 2014, 24,
5704–5709.
[7] a) M. Katragadda, J. D. Lambris, Protein Expres. Purif. 2006, 47, 289–295;
b) J. Broos, E. Gabellieri, E. Beimans-Oldehinkel, G. B. Strambini, Protein
Sci. 2003, 12, 1991–2000.
[8] a) F. Crestey, V. Collot, S. Stiebing, S. Rault, Tetrahedron 2006, 62, 7772–
7775; b) F. Cretey, V. Collot, S. Stiebing, J. F. Lohier, J. S. O. Santos, S.
Rault, Tetrahedron Lett. 2007, 48, 2457–2460; c) M. Jeanty, F. Suzenet, G.
Guillaumet, J. Org. Chem. 2008, 73, 7390–7393.
[9] R. Sanchez-Obregon, A. G. Fallis, Can. J. Chem. 1992, 70, 1531–1536.
[10] L. Lecointe, V. Rolland-Fulcrand, M. L. Roumestant, Ph. Viallefont, J.
Martinez, Tetrahedron: Asymmetry 1998, 9, 173–1758.
[11] S. Nakano, Y. Minamino, F. Hasebe, S. Ito, ACS Catal. 2019, 9, 10152–
10158.
[12] M. Winn, D. Francis, J. Micklefield, Angew. Chem. Int. Ed. 2018, 57, 6830–
6833; Angew. Chem. 2018, 130, 6946–6949.
[13] a) G. V. Röschenthaler, V. P. Kukhar, I. B. Kulik, M. Y. Belik, A. E.
Sorochinsky, E. B. Rusanov, V. A. Soloshonok, Tetrahedron Lett. 2012, 53,
539–542; b) K. V. Turcheniuk, K. O. Poliashko, V. P. Kukhar, A. B.
Rozhenko, V. A. Soloshonok, A. E. Sorochinsky, Chem. Commun. 2012,
48, 11519–11521.
Scheme 3. Disassembly of Ni-complex 4a.
Scheme 4. Fmoc protection of (S)-1.
Communications
doi.org/10.1002/ejoc.202100485
2964Eur. J. Org. Chem. 2021, 2962–2965 www.eurjoc.org © 2021 The Authors. European Journal of Organic Chemistry published
by Wiley-VCH GmbH
Wiley VCH Mittwoch, 21.07.2021
2121 - closed* / 206417 [S. 2964/2965] 1
[14] a) P. Bravo, A. Farina, V. P. Kukhar, A. L. Markovsky, S. V. Meille, V. A.
Soloshonok, A. E. Sorochinsky, F. Viani, M. Zanda, C. Zappala, J. Org.
Chem. 1997, 62, 3424–3425; b) V. A. Soloshonok, T. Hayashi, Tetrahedron:
Asymmetry 1994, 5, 1091–1094; c) V. A. Soloshonok, A. G. Kirilenko, V. P.
Kukhar, G. Resnati, Tetrahedron Lett. 1993, 34, 3621–3624.
[15] a) S. Zhou, J. Wang, X. Chen, J. L. Aceña, V. A. Soloshonok, H. Liu, Angew.
Chem. Int. Ed. 2014, 53, 7883–7886; Angew. Chem. 2014, 126, 8017–
8020; b) R. Takeda, A. Kawamura, A. Kawashima, T. Sato, H. Moriwaki, K.
Izawa, K. Akaji, S. Wang, H. Liu, J. L. Aceña, V. A. Soloshonok, Angew.
Chem. Int. Ed. 2014, 53, 12214–12217; Angew. Chem. 2014, 126, 12410–
12413; c) Y. Nian, J. Wang, S. Zhou, S. Wang, H. Moriwaki, A. Kawashima,
V. A. Soloshonok, H. Liu, Angew. Chem. Int. Ed. 2015, 54, 12918–12922;
d) N. Wang, J. Xu, H. Mei, H. Moriwaki, K. Izawa, V. A. Soloshonok, J. Han,
Chin. J. Org. Chem. 2021, doi: 10.6023/cjoc202102043.
[16] a) J. Han, T. T. Romoff, H. Moriwaki, H. Konno, V. A. Soloshonok, ACS
Omega 2019, 4, 18942–18947; b) T. T. Romoff, A. B. Palmer, N. Mansour,
C. J. Creighton, T. Miwa, Y. Ejima, H. Moriwaki, V. A. Soloshonok, Org.
Process Res. Dev. 2017, 21, 732–739.
[17] a) T. K. Ellis, V. M. Hochla, V. A. Soloshonok, J. Org. Chem. 2003, 68,
4973–4976; b) V. A. Soloshonok, X. Tang, V. J. Hruby, L. V. Meervelt, Org.
Lett. 2001, 3, 341–343.
[18] V. A. Soloshonok, V. P. Kukhar, S. V. Galushko, N. Y. Svistunova, D. V.
Avilov, N. A. Kuzmina, N. I. Raevski, Y. T. Struchkov, A. P. Pisarevsky, Y. N.
Belokon, J. Chem. Soc. Perkin Trans. 1 1993, 1993, 3143–3155.
[19] A. Kawamura, H. Moriwaki, G. V. Röschenthaler, K. Kawada, J. L. Aceña,
V. A. Soloshonok, J. Fluorine Chem. 2015, 171, 67–72.
[20] a) V. A. Soloshonok, D. V. Avilov, V. P. Kukhar, L. V. Meervelt, N.
Mischenko, Tetrahedron Lett. 1997, 38, 4903–4904; b) V. A. Soloshonok,
C. Cai, V. J. Hruby, Tetrahedron Lett. 2000, 41, 135–139; c) T. Yamada, T.
Okada, K. Sakaguchi, Y. Ohfune, H. Ueki, V. A. Soloshonok, Org. Lett.
2006, 8, 5625–5628.
[21] a) Y. Zou, J. Han, A. S. Saghyan, A. F. Mkrtchyan, H. Konno, H. Moriwaki,
K. Izawa, V. A. Soloshonok, Molecules 2020, 25, 2739; b) Y. Wang, X.
Song, J. Wang, H. Moriwaki, V. A. Soloshonok, H. Liu, Amino Acids 2017,
49, 1487–1520.
[22] a) Y. Shigeno, J. Han, V. A. Soloshonok, H. Moriwaki, W. Fujiwara, H.
Konno, Chirality 2021, 33, 115–123; b) B. Fu, R. Takeda, Y. Zou, H. Konno,
H. Moriwaki, H. Abe, J. Han, K. Izawa, V. A. Soloshonok, Chirality 2020,
32, 1354–1360; c) T. T. Romoff, B. G. Ignacio, N. Mansour, A. B. Palmer,
C. J. Creighton, H. Abe, H. Moriwaki, J. Han, H. Konno, V. A. Soloshonok,
Org. Process Res. Dev. 2020, 24, 294–300; d) Y. Tokairin, Y. Shigeno, J.
Han, G. V. Röschenthaler, H. Konno, H. Moriwaki, V. A. Soloshonok,
ChemistryOpen 2020, 9, 93–96; e) H. Mei, J. Han, R. Takeda, T. Sakamoto,
T. Miwa, Y. Minamitsuji, H. Moriwaki, H. Abe, V. A. Soloshonok, ACS
Omega 2019, 4, 11844–11851; f) Z. Yin, H. Moriwaki, H. Abe, T. Miwa, J.
Han, V. A. Soloshonok, ChemistryOpen 2019, 8, 701.
[23] Y. Nian, J. Wang, H. Moriwaki, V. A. Soloshonok, H. Liu, Dalton Trans.
2017, 46, 4191–4198.
[24] a) V. A. Soloshonok, H. Ueki, J. Am. Chem. Soc. 2007, 129, 2426–2427;
b) V. A. Soloshonok, T. Ono, H. Ueki, N. Vanthuyne, T. S. Balaban, J.
Bürck, H. Fliegl, W. Klopper, J. V. Naubron, T. T. Tam, A. F. Drake, C.
Roussel, J. Am. Chem. Soc. 2010, 132, 10477–10483.
[25] a) H. Mei, Z. Yin, T. Miwa, H. Moriwaki, H. Abe, J. Han, V. A. Soloshonok,
Symmetry 2019, 11, 578; b) H. Mei, T. Hiramatsu, R. Takeda, H. Moriwaki,
H. Abe, J. Han, V. A. Soloshonok, Org. Process Res. Dev. 2019, 23, 629–
634.
Manuscript received: April 19, 2021
Revised manuscript received: May 6, 2021
Accepted manuscript online: May 10, 2021
Communications
doi.org/10.1002/ejoc.202100485
2965Eur. J. Org. Chem. 2021, 2962–2965 www.eurjoc.org © 2021 The Authors. European Journal of Organic Chemistry published
by Wiley-VCH GmbH
Wiley VCH Mittwoch, 21.07.2021
2121 - closed* / 206417 [S. 2965/2965] 1
